滤泡淋巴瘤的治疗策略.ppt

* * * * * CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; CRu, unconfirmed complete response; CVP, cyclophosphamide, vincristine, prednisone; FCM, fludarabine, cyclophosphamide, mitoxantrone; FL, follicular lymphoma; PR, partial response; R, rituximab. ? This question was addressed in the PRIMA trial with data presented at the 2010 American Society of Clinical Oncology annual meeting. Patients with follicular lymphoma, including those with follicular lymphoma grade 3, were treated with either R-CHOP, R-CVP, or rituximab with a fludarabine-containing regimen based on the physician’s choice. Patients who responded were randomized to either observation or to rituximab maintenance with 1 dose every 8 weeks for 2 years. ? For more information, go online to: /Oncology/Conference%20Coverage/Clin%20Onc%20June%202010/Tracks/Hematologic%20Malignancies/Capsules/8004.aspx Evolving Standards of Care in Non-Hodgkins Lymphoma * CR, complete response; FL, follicular lymphoma; Maint, maintenance; Ph, phase; PR, partial response; QoL, quality of life; TTF, time to treatment failure. Richard I. Fisher, MD: The RESORT E4402 trial is an important study addressing the role of rituximab maintenance therapy in low tumor burden follicular lymphoma. In this trial, patients who achieved complete or partial remission to 4 weeks of frontline rituximab were randomized to maintenance rituximab every 3 months until treatment failure or retreatment with rituximab only at the time of treatment failure. The primary endpoint was time to treatment failure, and the median follow-up was 3.8 years. As background, it has been known for a long time that patients with low tumor burden follicular lymphoma do well with short-term rituximab monotherapy. Additional data have suggested that they experience even more favorable outcomes when given maintenance rituximab after the initial dosing period.[1] However, a small, underpowered randomized study from Hainsworth and col